SCHEMBL20510688

SCHEMBL20510688

CC(=O)NC(CSC(=O)OCc1oc(=O)oc1C)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PSMB11 A5LHX3 1/20 0.35
▸ PSMA7 O14818 1/20 0.35
▸ PSMB1 P20618 1/20 0.35
▸ PSMA1 P25786 1/20 0.35
▸ PSMA2 P25787 1/20 0.35
▸ PSMA3 P25788 1/20 0.35
▸ PSMA4 P25789 1/20 0.35
▸ PSMB8 P28062 1/20 0.35
▸ PSMB9 P28065 1/20 0.35
▸ PSMA5 P28066 1/20 0.35
▸ PSMB4 P28070 1/20 0.35
▸ PSMB6 P28072 1/20 0.35
▸ PSMB5 P28074 1/20 0.35
▸ PSMB10 P40306 1/20 0.35
▸ PSMB3 P49720 1/20 0.35
▸ PSMB2 P49721 1/20 0.35
▸ PSMA6 P60900 1/20 0.35
▸ SF3B3 Q15393 1/20 0.35
▸ PSMA8 Q8TAA3 1/20 0.35
▸ PSMB7 Q99436 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18650397 1.00 PSMB11 (0.35) PSMB11PSMA7PSMB1PSMA1PSMA2
SCHEMBL18631761 1.00 PSMB11 (0.35) PSMB11PSMA7PSMB1PSMA1PSMA2
SCHEMBL18631756 0.91 TYR (0.37) FOLH1CHRM1TBXA2RADRA1APPARG
SCHEMBL18650384 0.91 TYR (0.37) FOLH1CHRM1TBXA2RADRA1APPARG
SCHEMBL18650403 0.89 TACR1 (0.33) FOLH1TACR1
SCHEMBL18653810 0.87 KDM4E (0.37) FOLH1MAPTKDM4EALDH1A1RXFP1
SCHEMBL20122450 0.85 ACE (0.37) FOLH1CHRM1TBXA2RADRA1A
SCHEMBL20122425 0.85 FOLH1 (0.32) FOLH1CHRM1TBXA2RADRA1A
SCHEMBL18653811 0.84 PAM (0.38) PSMB11PSMA7PSMB1PSMA1PSMA2
SCHEMBL20510285 0.80 FOLH1 (0.38) FOLH1MAPTALOX15BLMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018174839-A1 CYSTEINE, N-ACETYLCYSTEINE AND PENICILLAMINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE NGUYEN MARK QUANG (US) 2018-09-27 — — WO disclosed
Send feedback